remimazolam + propofol + alfentanil

Remimazolam + propofol + alfentanil is an intravenous anesthetic combination being investigated by the First Affiliated Hospital of Zhejiang University. This drug regimen is designed for deep sedation and analgesia during procedures such as painless bronchoscopy (tracheoscopy), specifically to reduce the incidence of hypoxia in high-risk patients. The combination leverages the distinct pharmacological profiles of its components: remimazolam, a short-acting benzodiazepine that acts as a GABA-A receptor agonist; propofol, a sedative-hypnotic that modulates GABA-A receptors; and alfentanil, a potent, short-acting mu-opioid receptor agonist. By combining these agents, clinicians aim to achieve stable anesthesia with a lower dose of propofol, thereby minimizing respiratory and circulatory depression while ensuring rapid recovery and effective suppression of the cough reflex.

Other names

remimazolam combined with propofol and alfentanil